Document Detail

Cinacalcet treatment of primary hyperparathyroidism.
MedLine Citation:
PMID:  21461394     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Although parathyroidectomy remains the only curative approach to most primary hyperparathyroidism cases, medical treatment with cinacalcet HCl has been proven to be a reasonable alternative for several patient subgroups. Cinacalcet almost always controls hypercalcemia and hypophosphatemia sufficiently. PTH levels are lowered, and cognitive parameters improve. While an increase in bone mineral density DEXA scan scores was not demonstrated in cinacalcet trials, the same applies to more than half of patients after parathyroidectomy. Medical therapy should be first choice in patients with hyperplasia in all glands rather than an isolated adenoma (10-15%), patients with persisting HPT following unsuccessful surgery or inoperable cases due to comorbidities, and patients detected in lab screens for hypercalcemia before developing symptoms who should be treated early but are usually reluctant to undergo surgery. Nephrolithiasis was not found to occur more frequently in cinacalcet trial groups, but urine calcium excretion as one major risk factor of this complication of primary HPT may increase on cinacalcet. Patients carrying the rs1042636 polymorphism of the calcium-sensing receptor gene respond more sensitively to cinacalcet and have a higher risk of calcium stone formation. Cinacalcet is usually administered twice daily but three or four doses per day should be discussed to mimic the beneficial pulsatile PTH-pattern.
H M Rothe; O Liangos; P Biggar; A Petermann; M Ketteler
Related Documents :
22451584 - Pulmonary arterial hypertension in patients treated by dasatinib.
21760844 - Clinical, radiologic, and functional evaluation of 304 patients with bronchiectasis.
3035634 - The kock continent ileostomy--radiology of dysfunctions.
12526944 - Safety and steroid-sparing experience using infliximab for crohn's disease at a pediatr...
10573334 - Photopenic bone scan osteomyelitis: a clinical perspective.
19545554 - Response to hydroxyurea in beta thalassemia major and intermedia: experience in western...
Publication Detail:
Type:  Journal Article     Date:  2011-03-06
Journal Detail:
Title:  International journal of endocrinology     Volume:  2011     ISSN:  1687-8345     ISO Abbreviation:  Int J Endocrinol     Publication Date:  2011  
Date Detail:
Created Date:  2011-04-04     Completed Date:  2011-07-14     Revised Date:  2011-07-28    
Medline Journal Info:
Nlm Unique ID:  101516376     Medline TA:  Int J Endocrinol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  415719     Citation Subset:  -    
Division of Nephrology and Hypertension, Medical Department, Klinikum Coburg III, D-96450 Coburg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Measuring distributional inequality: relative body mass index distributions by gender, race/ethnicit...
Next Document:  MicroRNA as a Novel Modulator in Head and Neck Squamous Carcinoma.